Skip to content
2000
Volume 21, Issue 1
  • ISSN: 1573-4056
  • E-ISSN: 1875-6603
file format pdf download PDF
file format text download EPUB
side by side viewer icon HTML

Abstract

This study aimed to investigate the utility of ultrasonic attenuation imaging (ATI) in assessing the relationship between hepatic fat content and lipid metabolism in patients with type 2 diabetes mellitus (T2DM).

239 patients diagnosed with T2DM were included, with liver fat quantified using proton density fat fraction (PDFF). We analyzed the variance in ATI across various grades of fatty liver and its correlation with clinical parameters. Additionally, a receiver operating characteristic curve (ROC) was employed to evaluate the diagnostic accuracy of ATI for different degrees of fatty liver, determining optimal diagnostic thresholds while calculating sensitivity and specificity. Furthermore, we assessed the reliability of ATI and SWE in measuring liver acoustic attenuation and elastic stiffness using the intraclass correlation coefficient (ICC).

We observed significant variations in ATI across different grades of fatty liver (<0.001). ATI exhibited positive correlations with SWE, BMI, GLU (OH), steatosis grade, ALT, TG, and UA, while demonstrating a negative correlation with HDL-c. Notably, the correlation coefficient with steatosis grade was 0.784, indicating a strong association. The equation for the stepwise multiple linear regression model used is as follows: ATI=0.338+0.014×TG+0.052×BMI+0.001×ALT+0.113×SWE. AUROCs indicated the best cutoffs for ATI in different degrees of steatosis to be as follows: ≥ S1 = 0.665 dB·cm-1·MHz-1 (AUC = 0.899); ≥ S2 = 0.695 dB·cm-1·MHz-1 (AUC = 0.939); ≥ S3 = 0.745 dB·cm-1·MHz-1 (AUC = 0.937). The ICC values for ATI and SWE in liver-mimicking measurements exceeded 0.75 (<0.001), signifying excellent repeatability.

The ATI could quantitatively assess the severity of fatty liver, enabling effective identification of patients suitable for liver biopsy referral.

© 2025 The Author(s).
© 2025 The Author(s). Published by Bentham Science Publishers. This is an open access article published under CC BY 4.0 https://creativecommons.org/licenses/by/4.0/legalcode
Loading

Article metrics loading...

/content/journals/cmir/10.2174/0115734056335310250217064323
2025-01-01
2025-10-31

  • From This Site

    /content/journals/cmir/10.2174/0115734056335310250217064323
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

/deliver/fulltext/cmir/21/1/CMIR-21-E15734056335310.html?itemId=/content/journals/cmir/10.2174/0115734056335310250217064323&mimeType=html&fmt=ahah

References

  1. WongW.K. ChanW.K. Nonalcoholic fatty liver disease: A global perspective.Clin. Ther.202143347349910.1016/j.clinthera.2021.01.00733526312
     [Google Scholar]
  2. TargherG. CoreyK.E. ByrneC.D. RodenM. The complex link between NAFLD and type 2 diabetes mellitus — Mechanisms and treatments.Nat. Rev. Gastroenterol. Hepatol.202118959961210.1038/s41575‑021‑00448‑y33972770
     [Google Scholar]
  3. LeeY.S. YooY.J. JungY.K. KimJ.H. SeoY.S. YimH.J. KimI.H. LeeS.Y. KimB.H. KimJ.W. LeeC.H. YeonJ.E. KwonS.Y. UmS.H. ByunK.S. Multiparametric MR is a valuable modality for evaluating disease severity of nonalcoholic fatty liver disease.Clin. Transl. Gastroenterol.2020114e0015710.14309/ctg.000000000000015732251018
     [Google Scholar]
  4. FergusonD. FinckB.N. Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus.Nat. Rev. Endocrinol.202117848449510.1038/s41574‑021‑00507‑z34131333
     [Google Scholar]
  5. KleinerD.E. BruntE.M. WilsonL.A. BehlingC. GuyC. ContosM. CummingsO. YehM. GillR. ChalasaniN. Neuschwander-TetriB.A. DiehlA.M. DasarathyS. TerraultN. KowdleyK. LoombaR. BeltP. TonasciaJ. LavineJ.E. SanyalA.J. Nonalcoholic Steatohepatitis Clinical Research Network Association of histologic disease activity with progression of nonalcoholic fatty liver disease.JAMA Netw. Open2019210e191256510.1001/jamanetworkopen.2019.1256531584681
     [Google Scholar]
  6. TokushigeK. IkejimaK. OnoM. EguchiY. KamadaY. ItohY. AkutaN. YonedaM. IwasaM. YonedaM. OtsukaM. TamakiN. KogisoT. MiwaH. ChayamaK. EnomotoN. ShimosegawaT. TakeharaT. KoikeK. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020.J. Gastroenterol.2021561195196310.1007/s00535‑021‑01796‑x34533632
     [Google Scholar]
  7. PowellE.E. WongV.W.S. RinellaM. Non-alcoholic fatty liver disease.Lancet2021397102902212222410.1016/S0140‑6736(20)32511‑333894145
     [Google Scholar]
  8. KhanR.S. NewsomeP.N. Fat and fibrosis: Does empagliflozin impair the progression of nonalcoholic steatohepatitis in patients with type 2 diabetes mellitus?Dig. Dis. Sci.202065234234410.1007/s10620‑019‑05573‑y30847693
     [Google Scholar]
  9. GinèsP. KragA. AbraldesJ.G. SolàE. FabrellasN. KamathP.S. Liver cirrhosis.Lancet2021398103081359137610.1016/S0140‑6736(21)01374‑X34543610
     [Google Scholar]
  10. YoshizawaE YamadaA. MRI-derived proton density fat fraction.J Med Ultrason (2001)202148449750610.1007/s10396‑021‑01135‑w
     [Google Scholar]
  11. TamakiN. AjmeraV. LoombaR. Non-invasive methods for imaging hepatic steatosis and their clinical importance in NAFLD.Nat. Rev. Endocrinol.2022181556610.1038/s41574‑021‑00584‑034815553
     [Google Scholar]
  12. NewsomeP.N. SassoM. DeeksJ.J. ParedesA. BoursierJ. ChanW.K. YilmazY. CzernichowS. ZhengM.H. WongV.W.S. AllisonM. TsochatzisE. AnsteeQ.M. SheridanD.A. EddowesP.J. GuhaI.N. CobboldJ.F. ParadisV. BedossaP. MietteV. Fournier-PoizatC. SandrinL. HarrisonS.A. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: A prospective derivation and global validation study.Lancet Gastroenterol. Hepatol.20205436237310.1016/S2468‑1253(19)30383‑832027858
     [Google Scholar]
  13. ChalasaniN. YounossiZ. LavineJ.E. CharltonM. CusiK. RinellaM. HarrisonS.A. BruntE.M. SanyalA.J. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American association for the study of liver diseases.Hepatology201867132835710.1002/hep.2936728714183
     [Google Scholar]
  14. HeinitzS. MüllerJ. JenderkaK.V. SchlöglH. StumvollM. BlüherM. BlankV. KarlasT. The application of high-performance ultrasound probes increases anatomic depiction in obese patients.Sci. Rep.20231311629710.1038/s41598‑023‑43509‑937770538
     [Google Scholar]
  15. KimuraS. TanakaK. OedaS. InoueK. InadomiC. KubotsuY. YoshiokaW. OkadaM. IsodaH. KuwashiroT. AkiyamaT. KurashigeA. OshimaA. OshimaM. MatsumotoY. KawaguchiA. AnzaiK. SueokaE. AishimaS. TakahashiH. Effect of skin–capsular distance on controlled attenuation parameter for diagnosing liver steatosis in patients with nonalcoholic fatty liver disease.Sci. Rep.20211111564110.1038/s41598‑021‑94970‑334341368
     [Google Scholar]
  16. ShaoC. YeJ. DongZ. LiF. LinY. LiaoB. FengS. ZhongB. Steatosis grading consistency between controlled attenuation parameter and MRI-PDFF in monitoring metabolic associated fatty liver disease.Ther. Adv. Chronic Dis.2021122040622321103311910.1177/2040622321103311934408822
     [Google Scholar]
  17. FrancqueS M MarchesiniG KautzA Non-alcoholic fatty liver disease: A patient guideline.JHEP Rep20213510032210.1016/j.jhepr.2021.100322
     [Google Scholar]
  18. LomonacoR. Godinez LeivaE. BrilF. ShresthaS. MansourL. BuddJ. Portillo RomeroJ. SchmidtS. ChangK.L. SamrajG. MalatyJ. HuberK. BedossaP. KalavalapalliS. MarteJ. BarbD. PoultonD. FanousN. CusiK. Advanced liver fibrosis is common in patients with type 2 diabetes followed in the outpatient setting: The need for systematic screening.Diabetes Care202144239940610.2337/dc20‑199733355256
     [Google Scholar]
  19. DrożdżK. NabrdalikK. HajzlerW. KwiendaczH. GumprechtJ. LipG.Y.H. Metabolic-associated fatty liver disease (MAFLD), diabetes, and cardiovascular disease: Associations with fructose metabolism and gut microbiota.Nutrients202114110310.3390/nu1401010335010976
     [Google Scholar]
  20. MantovaniA. PetraccaG. BeatriceG. TilgH. ByrneC.D. TargherG. Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: An updated meta-analysis of 501 022 adult individuals.Gut202170596296910.1136/gutjnl‑2020‑32257232938692
     [Google Scholar]
  21. AjmeraV. CepinS. TesfaiK. HofflichH. CadmanK. LopezS. MadambaE. BettencourtR. RichardsL. BehlingC. SirlinC.B. LoombaR. A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes.J. Hepatol.202378347147810.1016/j.jhep.2022.11.01036410554
     [Google Scholar]
  22. SimonT.G. RoelstraeteB. SharmaR. KhaliliH. HagströmH. LudvigssonJ.F. Cancer risk in patients with biopsy‐confirmed nonalcoholic fatty liver disease: A population‐based cohort study.Hepatology20217452410242310.1002/hep.3184533811766
     [Google Scholar]
  23. JangJ.K. KimS.Y. YooI.W. ChoY.B. KangH.J. LeeD.H. Diagnostic performance of ultrasound attenuation imaging for assessing low-grade hepatic steatosis.Eur. Radiol.20223232070207710.1007/s00330‑021‑08269‑y34549325
     [Google Scholar]
  24. FerraioliG. MaiocchiL. RacitiM.V. TinelliC. De SilvestriA. NichettiM. De CataP. RondanelliM. ChiovatoL. CalliadaF. FiliceC. Detection of liver steatosis with a novel ultrasound-based technique: A pilot study using MRI-derived proton density fat fraction as the gold standard.Clin. Transl. Gastroenterol.20191010e0008110.14309/ctg.000000000000008131609745
     [Google Scholar]
  25. GuJ. LiuS. DuS. ZhangQ. XiaoJ. DongQ. XinY. Diagnostic value of MRI-PDFF for hepatic steatosis in patients with non-alcoholic fatty liver disease: A meta-analysis.Eur. Radiol.20192973564357310.1007/s00330‑019‑06072‑430899974
     [Google Scholar]
  26. FowlerK.J. VenkateshS.K. ObuchowskiN. MiddletonM.S. ChenJ. PepinK. MagnusonJ. BrownK.J. BatakisD. HendersonW.C. ShankarS.S. KamphausT.N. PasekA. CalleR.A. SanyalA.J. LoombaR. EhmanR. SamirA.E. SirlinC.B. SherlockS.P. Repeatability of MRI biomarkers in nonalcoholic fatty liver disease: The NIMBLE consortium.Radiology20233091e23109210.1148/radiol.23109237815451
     [Google Scholar]
  27. LinH. LeeH.W. YipT.C.F. TsochatzisE. PettaS. BugianesiE. YonedaM. ZhengM.H. HagströmH. BoursierJ. CallejaJ.L. GohG.B.B. ChanW.K. Gallego-DuránR. SanyalA.J. de LédinghenV. NewsomeP.N. FanJ.G. CastéraL. LaiM. HarrisonS.A. Fournier-PoizatC. WongG.L.H. PennisiG. ArmandiA. NakajimaA. LiuW.Y. ShangY. de Saint-LoupM. LlopE. TehK.K.J. Lara-RomeroC. AsgharpourA. MahgoubS. ChanM.S.W. CanivetC.M. Romero-GomezM. KimS.U. WongV.W.S. VCTE-Prognosis Study Group Vibration-controlled transient elastography scores to predict liver-related events in steatotic liver disease.JAMA2024331151287129710.1001/jama.2024.144738512249
     [Google Scholar]
  28. SanyalA.J. FoucquierJ. YounossiZ.M. HarrisonS.A. NewsomeP.N. ChanW.K. YilmazY. De LedinghenV. CostentinC. ZhengM.H. Wai-Sun WongV. ElkhashabM. HussR.S. MyersR.P. RouxM. LabourdetteA. DestroM. Fournier-PoizatC. MietteV. SandrinL. BoursierJ. Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using fibroscan-based agile scores.J. Hepatol.202378224725910.1016/j.jhep.2022.10.03436375686
     [Google Scholar]
  29. EddowesP.J. SassoM. AllisonM. TsochatzisE. AnsteeQ.M. SheridanD. GuhaI.N. CobboldJ.F. DeeksJ.J. ParadisV. BedossaP. NewsomeP.N. Accuracy of fibroscan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease.Gastroenterology201915661717173010.1053/j.gastro.2019.01.04230689971
     [Google Scholar]
  30. TadaT. KumadaT. ToyodaH. NakamuraS. ShibataY. YasudaS. WatanukiY. TsujiiK. FukudaN. FujiokaM. TakeshimaK. NiwaF. OgawaS. HashinokuchiS. KataokaS. IchikawaH. IijimaH. Attenuation imaging based on ultrasound technology for assessment of hepatic steatosis: A comparison with magnetic resonance imaging‐determined proton density fat fraction.Hepatol. Res.202050121319132710.1111/hepr.1356332876367
     [Google Scholar]
  31. YooJ. LeeJ.M. JooI. LeeD.H. YoonJ.H. KangH.J. AhnS.J. Reproducibility of ultrasound attenuation imaging for the noninvasive evaluation of hepatic steatosis.Ultrasonography202039212112910.14366/usg.1903431693842
     [Google Scholar]
  32. BaoJ. LvY. WangK. WangQ. ChenY. DongY. ZhuY. WangW. A comparative study of ultrasound attenuation imaging, controlled attenuation parameters, and magnetic resonance spectroscopy for the detection of hepatic steatosis.J. Ultrasound Med.20234271481148910.1002/jum.1615836583414
     [Google Scholar]
  33. HondaY. YonedaM. ImajoK. NakajimaA. Elastography techniques for the assessment of liver fibrosis in non-alcoholic fatty liver disease.Int. J. Mol. Sci.20202111403910.3390/ijms2111403932516937
     [Google Scholar]
  34. McPhersonS. ArmstrongM.J. CobboldJ.F. CorlessL. AnsteeQ.M. AspinallR.J. BarclayS.T. BrennanP.N. CacciottoloT.M. GoldinR.D. HallsworthK. HebditchV. JackK. JarvisH. JohnsonJ. LiW. MansourD. McCallumM. MukhopadhyaA. ParkerR. RossV. RoweI.A. SrivastavaA. ThiagarajanP. ThompsonA.I. TomlinsonJ. TsochatzisE.A. YeomanA. AlazawiW. Quality standards for the management of non-alcoholic fatty liver disease (NAFLD): Consensus recommendations from the British association for the study of the liver and british society of gastroenterology NAFLD special interest group.Lancet Gastroenterol. Hepatol.20227875576910.1016/S2468‑1253(22)00061‑935490698
     [Google Scholar]
  35. StefanN. CusiK. A global view of the interplay between non-alcoholic fatty liver disease and diabetes.Lancet Diabetes Endocrinol.202210428429610.1016/S2213‑8587(22)00003‑135183303
     [Google Scholar]
/content/journals/cmir/10.2174/0115734056335310250217064323
Loading
Correlation between Liver fat Content Determined by Ultrasonic Attenuation Imaging and Lipid Metabolism in Patients with Non-Alcoholic Fatty Liver Disease
Curr. Med. Imaging 21, E15734056335310 (2025); https://doi.org/10.2174/0115734056335310250217064323
/content/journals/cmir/10.2174/0115734056335310250217064323
/content/journals/cmir/10.2174/0115734056335310250217064323
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher's website along with the published article.

file format download Download

  • Article Type:     Research Article
Keyword(s): Attenuation imaging; Intraclass correlation coefficient; Non-alcoholic fatty liver disease; Proton density fat fraction; Type 2 diabetes; Ultrasonic attenuation imaging

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test